Coherus BioSciences (Coherus BioSciences) Days Payable : 39.01 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Coherus BioSciences's average Accounts Payable for the three months ended in Dec. 2023 was $36.2 Mil. Coherus BioSciences's Cost of Goods Sold for the three months ended in Dec. 2023 was $84.6 Mil. Hence, Coherus BioSciences's Days Payable for the three months ended in Dec. 2023 was 39.01.

The historical rank and industry rank for Coherus BioSciences's Days Payable or its related term are showing as below:

CHRS' s Days Payable Range Over the Past 10 Years
Min: 53.66 Med: 99.38 Max: 441.12
Current: 62.6

During the past 12 years, Coherus BioSciences's highest Days Payable was 441.12. The lowest was 53.66. And the median was 99.38.

CHRS's Days Payable is ranked worse than
67.51% of 714 companies
in the Biotechnology industry
Industry Median: 149.875 vs CHRS: 62.60

Coherus BioSciences's Days Payable declined from Dec. 2022 (68.89) to Dec. 2023 (39.01). It may suggest that Coherus BioSciences accelerated paying its suppliers.

Coherus BioSciences Days Payable Historical Data

The historical data trend for Coherus BioSciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

441.12

199.55

99.38

72.09

53.66

Coherus BioSciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															68.89	93.98	96.42	92.59	39.01

Competitive Comparison

For the Biotechnology subindustry, Coherus BioSciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus BioSciences Days Payable Distribution

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Days Payable falls into.

Coherus BioSciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Coherus BioSciences's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (11.526	+	35.219)	/	2 )	/	158.992	*	365
=	23.3725					/	158.992	*	365
=	53.66

Coherus BioSciences's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (37.092	+	35.219)	/	2 )	/	84.567	*	365 / 4
=	36.1555					/	84.567	*	365 / 4
=	39.01

Coherus BioSciences Days Payable Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences (Coherus BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

8C5:Germany

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Executives

Dennis M Lanfear	director, officer: President and CEO	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell	officer: Chief Financial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael	officer: See Remarks	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider	officer: Chief Commercial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton	director	46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler	officer: Chief Scientific Officer	333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti	officer: Chief, Quality & Compliance	COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret	officer: Chief Financial Officer	ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper	director	150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson	director	ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas	director	1170 FAIRFAX STREET, BIRMINGHAM MI 48009